What is Liposarcoma?

Cancers known as sarcomas develop in the connective tissues, such as muscle, fat, and bone, that hold the body together. The type of sarcoma diagnosed in Toronto Mayor Rob Ford, liposarcoma, originates in fat cells that have been driven by random DNA errors into malignant growth, forming tumors.

George Demetri, MD, Director,
Center for Sarcoma and Bone Oncology

George Demetri, MD, Director of Dana-Farber’s Center for Sarcoma and Bone Oncology, notes that while sarcomas are not a common form of cancer, they are not rare: about 10,000 sarcoma cases are diagnosed in the United States each year.

Liposarcomas, which most often affect middle-age and older adults, develop as large, bulky masses inside the abdomen, causing no symptoms until they cause pain by pressing on vital structures. There are no known risk factors for this type of cancer, Demetri says.

Liposarcomas are classified as well-differentiated, dedifferentiated, mixoid, and pleomorphic. The latter are the most rare and most aggressive type, and Ford reportedly has a pleomorphic tumor.

They are diagnosed by examination of biopsied tissue, and Demetri says determining which type of liposarcoma a patient has is extremely important and “very challenging,” requiring special expertise and DNA testing.

Surgery, chemotherapy, and radiation are all used to treat liposarcoma. The prognosis depends on the type of liposarcoma, its size, and whether the cancer has spread.

“There is a lot of hope for patients with liposarcoma,” says Demetri. New drugs are being developed that home in on DNA abnormalities, or targets, within the tumor cells. Often these drugs inhibit overactive proteins or enzymes in the cancer that cause it to grow uncontrollably. Some drugs of this type are now in clinical trials.

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
Dana-Farber clinicians have been involved in the development of several new agents approved recently for B-cell acu… https://t.co/Oo3SiY79EN
Dana-Farber @danafarber
Dana-Farber #researchers have shown that clonal hematopoiesis of indeterminate potential (CHIP) - the presence of s… https://t.co/ZlmXSeyKfZ
Dana-Farber @danafarber
CRISPR, a powerful new tool for editing the #DNA instruction manual in animals and humans, is proving a boon to… https://t.co/pCzS3riHPS

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.